Aerovate Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Tim Noyes
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 19.1% |
| CEO tenure | 3.6yrs |
| CEO ownership | n/a |
| Management average tenure | 3.1yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely
Oct 01
Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
Jun 11Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
May 24Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 09We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate
Oct 17Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Jul 04Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 28A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Jan 06Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Oct 14Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
Jul 01We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth
Jan 22Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Sep 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$85m |
| Jun 30 2024 | n/a | n/a | -US$88m |
| Mar 31 2024 | n/a | n/a | -US$82m |
| Dec 31 2023 | US$3m | US$586k | -US$76m |
| Sep 30 2023 | n/a | n/a | -US$70m |
| Jun 30 2023 | n/a | n/a | -US$64m |
| Mar 31 2023 | n/a | n/a | -US$57m |
| Dec 31 2022 | US$704k | US$563k | -US$52m |
| Sep 30 2022 | n/a | n/a | -US$45m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$31m |
| Dec 31 2021 | US$5m | US$437k | -US$23m |
Compensation vs Market: Tim's total compensation ($USD3.07M) is above average for companies of similar size in the US market ($USD651.40K).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
CEO
Tim Noyes (62 yo)
3.6yrs
Tenure
US$3,070,657
Compensation
Mr. Timothy P. Noyes, MBA, also known as Tim, has been the Chief Executive Officer of Aerovate Therapeutics, Inc. since May 2021 and has been its Director since April 2021. Mr. Noyes serves as Venture Part...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.6yrs | US$3.07m | no data | |
| CFO & Treasurer | 3.8yrs | US$2.13m | 0.017% $ 13.1k | |
| Founder | 6.4yrs | US$2.88m | 0.049% $ 37.1k | |
| Chief Scientific Officer | 2.3yrs | US$433.20k | 0.0056% $ 4.2k | |
| Chief Medical Officer | 4.6yrs | US$1.63m | 0.019% $ 14.6k | |
| Head of Regulatory Affairs | 4.3yrs | no data | no data | |
| Executive Vice President of Development Operations | 2.7yrs | no data | no data | |
| Senior Vice President of Quality | 2.3yrs | no data | no data | |
| Executive Vice President of Clinical Development | 1.9yrs | no data | no data | |
| Senior Vice President of Clinical Development | 1.9yrs | no data | no data |
3.1yrs
Average Tenure
61yo
Average Age
Experienced Management: AVTE's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.7yrs | US$3.07m | no data | |
| Independent Director | 1.4yrs | no data | no data | |
| Independent Director | 1.9yrs | US$568.54k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$225.99k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$174.80k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$218.30k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$185.80k | 0% $ 0 | |
| Independent Chairman of the Board | 1.4yrs | US$363.25k | 0% $ 0 |
3.5yrs
Average Tenure
57yo
Average Age
Experienced Board: AVTE's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:20 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aerovate Therapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vamil Divan | Guggenheim Securities, LLC |
| Eun Kyung Yang | Jefferies LLC |
| Yuchen Ding | Jefferies LLC |